US4839161A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cosmetic products
Assignee: Unilever Patent Holdings BV
•
Filing: 1987-08-25
•
Granted: 1989-06-13
•
Expires: 2007-08-25
Abstract
Abstract A therapeutic composition for alleviating or preventing sun-induced desquamation comprises as active ingredients a C3 to C30 2-hydroxyalkanoic acid or an ester thereof together with a sunscreen active ingredient in a therapeutically acceptable vehicle. The active ingredients can also be used in the preparation of the composition for the treatment or prevention of this skin condition which can follow exposure to an excessive amount of sunlight.
Inventors
- 👤 Paul A. Bowser
- 👤 Ingrid C. Sturmey
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 06:12
CPC Classifications
A; A61; A61K; A61K8/00; A61K8/18; A61K8/30; A61K8/33; A61K8/37; A61K8/35; A61K8/36; A61K8/365; A61K8/375; A61Q; A61Q17/00; A61Q17/04; A61Q19/00; A61Q19/004
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
117 words
A method of alleviating the symptoms of sun-induced desquamation comprising topically applying to involved areas of the body an effective amount of composition comprising as active ingredients: (i) a therapeutically effective amount of from 0.1 20% by weight of a desquamation inhibitor selected from group consisting of 2-hydroxyalkanoic acids and esters thereof, having the structure: CH.sub.3 (CH.sub.2).sub.n CH.OH COOR where R is --H, C 2-10 alkyl or a monoglyceride, diglyceride or triglyceride residue, and n is 0, or an integer of from 1 to 27, and mixtures thereof; and (ii) a therapeutically effective amount of from 0.01 to 10% by weight of a sunscreen active ingredient or mixtures thereof, in a therapeutically acceptable vehicle for topical application.
Claim 2
Independent Claim
117 words
A method of alleviating the symptoms of sun-induced desquamation comprising topically applying to involved areas of the body an effective amount of composition comprising as active ingredients: (i) a therapeutically effective amount of from 0.1 20% by weight of a desquamation inhibitor selected from group consisting of 2-hydroxyalkanoic acids and esters thereof, having the structure: CH.sub.3 (CH.sub.2).sub.n CH.OH COOR where R is --H, C 2-10 alkyl or a monoglyceride, diglyceride or triglyceride residue, and n is 0, or an integer of from 1 to 27, and mixtures thereof; and (ii) a therapeutically effective amount of from 0.01 to 10% by weight of a sunscreen active ingredient or mixtures thereof, in a therapeutically acceptable vehicle for topical application.
Claim 3
Dependent Claim
39 words
The composition of claim 1, wherein the desquamation inhibitor is selected from the group consisting of: 2-hydroxypropanoic acid 2-hydroxytetranoic acid 2-hydroxyhexanoic acid 2-hydroxyoctanoic acid 2-hydroxydecanoic acid 2-hydroxydodecanoic acid 2-hydroxytetradecanoic acid 2-hydroxyhexadecanoic acid 2-hydroxyoctadecanoic acid 2-hydroxyoctaeicosanoic acid, and mixtures thereof.
Claim 4
Dependent Claim
72 words
The composition of claim 1, wherein the desquamation inhibitor is selected from the group consisting of: 2-hydroxypropanoic acid ethyl ester 2-hydroxypropanoic acid propyl ester 2-hydroxytetranoic acid ethyl ester 2-hydroxyhexanoic acid methyl ester 2-hydroxyhexanoic acid ethyl ester 2-hydroxyoctanoic acid hexyl ester 2-hydroxyoctanoic acid methyl ester 2-hydroxyoctanoic acid ethyl ester 2-hydroxyoctanoic acid pentyl ester 2-hydroxyoctanoic acid octyl ester 2-hydroxyoctadecanoic acid ethyl ester 2-hydroxyoctanoic acid monoglyceride 2-hydroxyoctanoic acid diglyceride 2-hydroxyoctanoic acid triglyceride, and mixtures thereof.
Claim 5
Dependent Claim
46 words
The composition of claim 1, wherein the sunscreen active ingredient is selected from the group consisting of: p-Aminobenzoic acid Ethyl dihydroxypropyl p-aminobenzoic acid Glyceryl p-aminobenzoic acid 2,4-Dihydroxy benzophenone 2-Ethoxyethyl-p-methoxycinnamate Di-ethanolamine p-methoxycinnamate 2-Ethylhexyl salicylate Homomenthyl salicylate 2-Phenylbenzimidazole-5-sulphonic acid Ethylhexyl p-methoxycinnamate 3-(4-Methylbenzylidine) camphor 2-Hydroxy-4-methoxy benzophenone Butylmethoxydibenzoylmethane 4-Isopropyl dibenzoylmethane
References Cited (Backward Citations)
US3098795A
Cited
DE1952057A1
Cited
DE1961146A1
Cited
GB1297928A
Cited
US4294852A
Cited
EP0007785A2
Cited
US4424234A
Cited
US4234599A
Cited
US4363763A
Cited
EP0086070A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-06-12 | 1992-12-12 | 1993-06-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-06-12 | 1996-12-12 | 1997-06-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-06-12 | 2000-12-12 | 2001-06-13 | $7700.00 | Window Closed / Lapsed |